Back to search
FDAFDA · Food and drugs·Recall number D-0462-2023

Clobazam Tablets, 10 mg, CIV, 100-count bottle, Rx only, Manufactured by Centaur Pharmaceuticals Pvt. Ltd., Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berlin, CT 06037, NDC 51991-900-01

Published March 22, 2023 · Recall initiated: March 2, 2023

Summary

FDA records drug Class II recall D-0462-2023, published March 22, 2023 and initiated March 2, 2023. Recalling firm: Breckenridge Pharmaceutical, Inc; Status: Terminated; Reported quantity: N/A; Lot: Lot # 5210085, Exp 12/2023; 5210248, Exp 01/2024; 5220796, Exp 07/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Potential risk of Cross Contamination

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Breckenridge Pharmaceutical, Inc
Distributor
USA nationwide.
Lot
Lot # 5210085, Exp 12/2023; 5210248, Exp 01/2024; 5220796, Exp 07/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clobazam Tablets, 10 mg, CIV, 100-count bottle, Rx only, Manufactured by Centaur Pharmaceuticals Pvt. Ltd., Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berlin, CT 06037, NDC 51991-900-01 recalled?

Yes. FDA published recall D-0462-2023 on March 22, 2023. Reported hazard: CGMP Deviations: Potential risk of Cross Contamination

What should I do if I have this product?

Voluntary: Firm initiated · Letter